Scientific rationale for the development of gene therapy strategies for Parkinson's disease
Résumé
The ever-evolving understanding of the neuronal systems involved in Parkinson's disease together with the recent advances in recombinant viral vector technology has lead to the development of several gene therapy applications that are now entering into clinical testing phase. To date, four fundamentally different approaches have been pursued utilizing recombinant adeno-associated virus and lentiviruses as vectors for delivery. These strategies aim either to restore the lost brain functions by substitution of enzymes critical for synthesis of neurotransmitters or neurotrophic factors as a means to boost the function of remaining neurons in the diseased brain. In this review we discuss the differences in mechanism of action and describe the scientific rationale behind the currently tested gene therapy approaches for Parkinson's disease in some detail and pinpoint their individual unique strengths and weaknesses
Mots clés
neurotrophic factors
neurorestoration
neuroprotection
enzyme replacement
dopamine
tyrosine hydroxylas
6-OHDA
AADC
COMT
DBS
DA
DAT
EIAV
FDG
FMT
GABA
GDNF
GFR
GP
GPi
Glu
GAD
GFP
GCH1
ICV
IgSP
L-DOPA
MPTP
NGF
NTN
PD
PDCP
PDRP
PPRS
PET
rAAV
rAd
rLV
BH4
5HT
STN
SNr
TH
UPDRS
VG
viral vectors
in vivo gene transfer
Origine : Fichiers produits par l'(les) auteur(s)
Loading...